Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847415 | 0.85 | KMT2A (0.45) | ALDH1A1CYP2D6CYP3A4NFKB1KCNH2 | |
| SCHEMBL847144 | 0.84 | KMT2A (0.49) | ALDH1A1CYP2D6CYP3A4NFKB1KCNH2 | |
| SCHEMBL847416 | 0.75 | TDP1 (0.64) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL11183020 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MAPTCYP3A4MEN1KMT2A | |
| SCHEMBL11719071 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MAPTCYP3A4MEN1KMT2A | |
| SCHEMBL847480 | 0.72 | MAPK1 (0.51) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL847404 | 0.72 | SMN1; SMN2 (0.57) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7828248 | 0.71 | ALDH1A1 (0.59) | ALDH1A1MAPTCYP3A4MEN1KMT2A | |
| SCHEMBL7828244 | 0.71 | ALDH1A1 (0.59) | ALDH1A1MAPTCYP3A4MEN1KMT2A | |
| SCHEMBL7513935 | 0.68 | MAPK1 (0.52) | ALDH1A1MAPTCYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | ALDH1A1 75/4885MAPT 2207/4885CYP2D6 26/4885 |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | ALDH1A1 75/4885MAPT 2207/4885CYP2D6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.